SEARCH

SEARCH BY CITATION

References

  • Abiko Y. and Kumagai Y. (2013) Interaction of Keap1 modified by 2-tert-butyl-1,4- benzoquinone with GSH: Evidence for S-transarylation. Chem. Res. Toxicol. 26, 10801087.
  • Ardley H. C., Scott G. B., Rose S. A., Tan N. G. S. and Robinson P. A. (2004) UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J. Neurochem. 90, 379391.
  • Bilguvar K., Tyagi N. K., Ozkara C. et al. (2013) Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc. Natl Acad. Sci. USA 110, 34893494.
  • Boudreaux D. A., Maiti T. K., Davies C. W. and Das C. (2010) Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl Acad. Sci. USA 107, 91179122.
  • Cartier A. E., Djakovic S. N., Salehi A., Wilson S. M., Masliah E. and Patrick G. N. (2009) Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J. Neurosci. 29, 78577868.
  • Choi J., Levey A. I., Weintraub S. T., Rees H. D., Gearing M., Chin L. S. and Li L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 1325613264.
  • Das C., Hoang Q. Q., Kreinbring C. A., Luchansky S. J., Meray R. K., Ray S. S., Lansbury P. T., Ringe D. and Petsko G. A. (2006) Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl Acad. Sci. USA 103, 46754680.
  • Eriksen J. L., Dawson T. M., Dickson D. W. and Petrucelli L. (2003) Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40, 453456.
  • Guillot T. S. and Miller G. W. (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149170.
  • Kawai H., Makino Y., Hirobe M. and Ohta S. (1998) Novel endogenous 1,2,3,4-tetrahydro- isoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J. Neurochem. 70, 745751.
  • Kawai H., Kotake Y. and Ohta S. (2000a) Inhibition of dopamine receptors by endogenous amines: binding to striatal receptors and pharmacological effects on locomotor activity. Bioorg. Med. Chem. Lett. 10, 16691671.
  • Kawai H., Kotake Y. and Ohta S. (2000b) Dopamine transporter and catechol-O-methyltrans- ferase activities are required for the toxicity of 1-(3′,4′-dihydroxybenzyl)-1,2,3,4-tetrahydro- isoquinoline. Chem. Res. Toxicol. 13, 12941301.
  • Koharudin L. M. I., Liu H., Di Maio R., Kodali R. B., Graham S. H. and Gronenborn A. M. (2010) Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proc. Natl Acad. Sci. USA 107, 68356840.
  • Kohno M., Ohta S. and Hirobe M. (1986) Tetrahydroisoquinoline and 1-methyl-tetrahydroiso- quinoline as novel endogenous amines in rat brain. Biochem. Biophys. Res. Commun. 140, 448454.
  • Kohta R., Kotake Y., Hosoya T. et al. (2010) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline binds with tubulin β, a substrate of parkin, and reduces its polyubiquitination. J. Neurochem. 114, 12911301.
  • Kotake Y., Tasaki Y., Makino Y., Ohta S. and Hirobe M. (1995) 1-Benzyl-1,2,3,4-tetrahydro- isoquinoline as a parkinsonism-inducing agent – a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 65, 26332638.
  • Kotake Y., Yoshida M., Ogawa M., Tasaki Y., Hirobe M. and Ohta S. (1996) Chronic admi- nistration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci. Lett. 217, 6971.
  • Kumagai Y., Shinkai Y., Miura T. and Cho A. K. (2012) The chemical biology of naphthoquinones and its environmental implications. Annu. Rev. Pharmacol. Toxicol. 52, 221247.
  • Laemmli U. K. (1970) Cleavage of structural proteins during assembly of head of bacterio- phage-T4. Nature 227, 680685.
  • Lau Y. S., Trobough K. L., Crampton J. M. and Wilson J. A. (1990) Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21, 181187.
  • LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G. and Selkoe D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 12141221.
  • Leroy E., Boyer R., Auburger G. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451452.
  • Liu Y. C., Fallon L., Lashuel H. A., Liu Z. H. and Lansbury P. T. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209218.
  • Maraganore D. M., Farrer M. J., Hardy J. A., Lincoln S. J., McDonnell S. K. and Rocca W. A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53, 18581860.
  • Meray R. K. and Lansbury P. T. (2007) Reversible monoubiquitination regulates the Parkin- son disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282, 1056710575.
  • Meredith G. E., Baldo B. A., Andrezjewski M. E. and Kelley A. E. (2008) The structural basis for mapping behavior onto the ventral striatum and its subdivisions. Brain Struct. Funct. 213, 1727.
  • Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B. and Levey A. I. (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156, 138148.
  • Miura T., Kakehashi H., Shinkai Y., Egara Y., Hirose R., Cho A. K. and Kumagai Y. (2011a) GSH-mediated S-transarylation of a quinone glyceraldehyde-3-phosphate dehydrogenase conjugate. Chem. Res. Toxicol. 24, 18361844.
  • Miura T., Shinkai Y., Hirose R., Iwamoto N., Cho A. K. and Kumagai Y. (2011b) Glyceraldehyde-3-phosphate dehydrogenase as a quinone reductase in the suppression of 1,2-naphthoquinone protein adduct formation. Free Radic. Biol. Med. 51, 20822089.
  • Morris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S. and Olson A. J. (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 16, 27852791.
  • Nishikawa K., Li H., Kawamura R. et al. (2003) Alterations of structure and hydrolase acti- vity of Parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304, 176183.
  • Ohta S., Kohno M., Makino Y., Tachikawa O. and Hirobe M. (1987) Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain - relation to Parkinson's disease. Biomed. Res. 8, 453456.
  • Osaka H., Wang Y. L., Takada K. et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12, 19451958.
  • Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C. and Ferrin T. E. (2004) UCSF chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 16051612.
  • Rudolph T. K. and Freeman B. A. (2009) Transduction of redox signaling by electrophile-protein reactions. Sci. Signal. 2, re7.
  • Sanner M. F. (1999) Phyton: a programming language for software integration and development. J. Mol. Graph. Model. 17, 5761.
  • Satoh J. and Kuroda Y. (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189, 113117.
  • Schlossmacher M. G., Frosch M. P., Gai W. P. et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 16551667.
  • Segura-Aguilar J., Paris I., Muñoz P., Ferrari E., Zecca L. and Zucca F. A. (2014) Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 10, 1111.
  • Setsuie R. and Wada K. (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51, 105111.
  • Setsuie R., Wang Y. L., Mochizuki H. et al. (2007) Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease- associated UCH-L1 193M mutant. Neurochem. Int. 50, 119129.
  • Tasaki Y., Makino Y., Ohta S. and Hirobe M. (1991) 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinso- nism-like behavior abnormalities. J. Neurochem. 57, 19401943.
  • Toyama T., Shinkai Y., Kaji T. and Kumagai Y. (2013) A convenient method to assess chemical modification of protein thiols by electrophilic metals. J. Toxicol. Sci. 38, 477484.
  • Trott O. and Olson A. J. (2010) Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multi- threading. J. Comput. Chem. 31, 455461.
  • Van Laar V. S., Mishizen A. J., Cascio M. and Hastings T. G. (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34, 487500.
  • Wilkinson K. D., Lee K., Deshpande S., Duerksenhughes P., Boss J. M. and Pohl J. (1989) The neuron-specific protein PGP-9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670673.
  • Wintermeyer P., Krüger R., Kuhn W. et al. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. NeuroReport 11, 20792082.
  • Zhang J., Hattori N., Leroy E., Morris H. R., Kubo S. I., Kobayashi T., Wood N. W., Polymeropoulos M. H. and Mizuno Y. (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord. 6, 195197.